IndustryCompany release

Armada Acquisition Corp. III to merge with cannabinoid API maker Brains Bioceutical

🇺🇸 Armada Acquisition Corp. III (AACI) · Thu 05 Nov 2026

The SPAC and Brains Bioceutical signed a definitive agreement on 5 November 2026, implying a pre-money equity value of about $750 million, with completion subject to closing conditions.

Armada Acquisition Corp. III (Nasdaq: AACI), a special purpose acquisition company, has signed a definitive business combination agreement with Brains Bioceutical. The agreement was dated 5 November 2026.

Brains Bioceutical makes cannabinoid active pharmaceutical ingredients (APIs) under EU-GMP standards. Its pipeline includes programmes in glaucoma, epilepsy, opioid use disorder and sleep.

The deal implies a pre-money equity value of about $750 million. The combined company would be called Brains Therapeutics Corp. and is expected to list on Nasdaq under the ticker "BAPI".

Completion has not yet happened and remains subject to closing conditions. The information available does not give further detail on those conditions, the timetable or the financing terms.

What it means for your team

  • Teams sourcing cannabinoid APIs should note that an EU-GMP supplier is heading for a US public listing, though nothing in the announcement changes current supply arrangements.
  • Regulatory and quality teams tracking cannabinoid-based development can watch the glaucoma, epilepsy, opioid use disorder and sleep programmes as the combined company takes shape.
  • The transaction is not completed, so the proposed name, ticker and valuation could still change before closing.

Company's press release (SEC filing): Armada Acquisition Corp. III ↗

Article written by VigiEye from the official source (Armada Acquisition Corp. III). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →